Additional file 3 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
This study presents the change from baseline in the mean of the B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit for relugolix in women with endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (11)
- Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis via openalex
- Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis via openalex
- Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire via openalex
- Medical Management of Endometriosis via openalex
- Progestin Therapy in Endometriosis via openalex
- Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- (no identifier) via openalex
- (no identifier) via openalex
- (no identifier) via openalex
- (no identifier) via openalex
Source provenance
- openalex
- last seen: 2026-05-13T18:34:15.591076+00:00